DHDDS Inhibitors
DHDDS inhibitors are a class of chemical compounds that specifically target and inhibit the enzyme DHDDS (dehydrodolichyl diphosphate synthase). This enzyme plays a crucial role in the synthesis of dolichol, an essential lipid molecule involved in various cellular processes. Dolichol serves as a carrier molecule for the glycosylation of proteins, a critical step in protein maturation and quality control within the endoplasmic reticulum (ER). DHDDS catalyzes the formation of dehydrodolichyl diphosphate, a precursor to dolichol, and its inhibition disrupts this biosynthetic pathway.
The mechanism of action of DHDDS inhibitors involves binding to the active site of the enzyme, thereby preventing its function. By interfering with DHDDS activity, these inhibitors disrupt the synthesis of dolichol, leading to a downstream impact on glycoprotein formation. Glycoproteins are essential for proper folding, stability, and trafficking of proteins within the cell, as well as for cell-cell communication through glycan-mediated interactions. Consequently, DHDDS inhibitors have the ability to affect a wide range of cellular processes that rely on glycosylation, including protein secretion, cell adhesion, and immune responses. Researchers have been exploring DHDDS inhibitors as valuable tools in understanding the role of glycosylation in cellular physiology and as agents for modulating glycoprotein-related pathways. Their use in the laboratory setting has provided insights into the significance of dolichol biosynthesis in various cellular contexts, shedding light on the complex interplay of glycosylation in health and disease.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits tyrosine kinases by specifically targeting the BCR-ABL fusion protein, disrupting its kinase activity, which is crucial in the pathogenesis of certain types of leukemia. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $256.00 | 18 | |
Tamoxifen acts as a selective estrogen receptor modulator by binding to estrogen receptors, blocking estrogen's effect on breast tissue, and indirectly inhibiting cellular processes driven by estrogen signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits tumor growth by targeting Raf kinases involved in cell division and angiogenesis, as well as VEGFR, which is critical for blood vessel formation in tumors. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase by binding to its adenosine triphosphate (ATP)-binding site, preventing the receptor's autophosphorylation and subsequent activation of downstream signaling pathways that promote cell proliferation. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $66.00 | 4 | |
Omeprazole inhibits the H+/K+ ATPase (proton pump) in gastric parietal cells, effectively reducing gastric acid secretion and its associated effects on the stomach lining and esophagus. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $252.00 $495.00 | 9 | |
Atorvastatin competitively inhibits HMG-CoA reductase, the enzyme responsible for converting HMG-CoA to mevalonate, a precursor of cholesterol, thus lowering cholesterol synthesis in the liver. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib blocks the activity of Janus kinase 1 and 2 (JAK1 and JAK2), enzymes involved in signaling pathways that regulate blood cell production and immune function, addressing the overactivity seen in myelofibrosis. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib inhibits multiple receptor tyrosine kinases, including those involved in tumor growth and angiogenesis, thereby preventing tumor cell proliferation and reducing tumor blood supply. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the 26S proteasome, a complex that degrades ubiquitinated proteins, leading to the accumulation of defective proteins and inducing apoptosis in cancer cells, particularly those of multiple myeloma. | ||||||